PUMA facilitates EMI1-promoted cytoplasmic Rad51 ubiquitination and inhibits DNA repair in stem and progenitor cells | Signal Transduction and Targeted Therapy
Puma Biotechnology Inc - AnnualReports.com
Puma Biotechnology und Pierre Fabre ändern die NERLYNX®-Lizenzvereinbarung, die neu auch Großchina einbezieht | Business Wire
Greenwich LifeSciences: Optimism On 'GP2' Breast Cancer Immunotherapy Candidate (NASDAQ:GLSI) | Seeking Alpha
PDF) Synergistic Effect of Expressed miR-128 and Puma Protein on Targeted Induction of Tumor Cell Apoptosis
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2020 Financial Results
Puma Biotechnology
Puma Biotechnology und Pierre Fabre schließen exklusiven Lizenzvertrag zur Entwicklung und Vermarktung von NERLYNX® (Neratinib) in Europa ab | Business Wire